E. Campo, WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. (International Agency for Research on Cancer, 2017.

D. A. Arber, The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia, Blood, vol.127, pp.2391-2405, 2016.

V. S. Hoffmann, The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries, Leukemia, vol.29, pp.1336-1343, 2015.

M. Höglund, F. Sandin, and B. Simonsson, Epidemiology of chronic myeloid leukaemia: an update, Ann. Hematol, vol.94, issue.2, pp.241-247, 2015.

J. M. Goldman and J. V. Melo, Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia, N. Engl. J. Med, vol.344, pp.1084-1086, 2001.

M. Delord, S. Foulon, J. Cayuela, P. Rousselot, and J. Bonastre, The rising prevalence of chronic myeloid leukemia in France, Leuk. Res, vol.69, pp.94-99, 2018.

S. Corm, Changes in the dynamics of the excess mortality rate in chronic phase-chronic myeloid leukemia over 1990-2007: a population study, Blood, vol.118, pp.4331-4337, 2011.
URL : https://hal.archives-ouvertes.fr/hal-02299262

H. Bower, Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population, J. Clin. Oncol, vol.34, pp.2851-2857, 2016.

A. Velpeau, Sur la resorption du pusaet sur l'alteration du sang dans les maladies clinique de persection nenemant. Premier observation, Rev Med, vol.2, p.216, 1827.

J. H. Bennett, Case of hypertrophy of the spleen and liver, in which death took place from suppuration of the blood, Edinburgh Med Sug J, vol.64, pp.413-423, 1845.

R. Virchow, . Weisses, and . Blut, Frorieps Notizen, vol.36, pp.151-156, 1845.

P. C. Nowell, A minute chromosome n human chronic granualocytic leukemia, Science, vol.132, pp.1497-1501, 1960.

P. J. Fialkow, S. M. Gartler, and A. Yoshida, Clonal origin of chronic myelocytic leukemia in man, Proc. Natl. Acad. Sci. U.S.A, vol.58, pp.1468-1471, 1967.

J. D. Rowley, Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining, Nature, vol.243, pp.290-293, 1973.

A. De-klein, A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia, Nature, vol.300, pp.765-767, 1982.

N. Heisterkamp, Localization of the c-ab1 oncogene adjacent to a translocation break point in chronic myelocytic leukaemia, Nature, vol.306, pp.239-242, 1983.

C. R. Bartram, Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia, Nature, vol.306, pp.277-280, 1983.

J. Groffen, Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22, Cell, vol.36, pp.93-99, 1984.

N. Heisterkamp, K. Stam, J. Groffen, A. De-klein, and G. Grosveld, Structural organization of the bcr gene and its role in the Ph' translocation, Nature, vol.315, pp.758-761, 1985.

E. Shtivelman, B. Lifshitz, R. P. Gale, and E. Canaani, Fused transcript of abl and bcr genes in chronic myelogenous leukaemia, Nature, vol.315, pp.550-554, 1985.

G. Q. Daley, R. A. Van-etten, and D. Baltimore, Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome, Science, vol.247, pp.824-830, 1990.

T. I. Mughal, Chronic myeloid leukemia: reminiscences and dreams, Haematologica, vol.101, pp.541-558, 2016.

D. Rea, J. Cayuela, and . Leucémie, , 2014.

B. J. Druker, Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells, Nat. Med, vol.2, pp.561-566, 1996.

S. Faderl, The biology of chronic myeloid leukemia, N. Engl. J. Med, vol.341, pp.164-172, 1999.

D. Perrotti, C. Jamieson, J. Goldman, and T. Skorski, Chronic myeloid leukemia: mechanisms of blastic transformation, J. Clin. Invest, vol.120, pp.2254-2264, 2010.

B. Calabretta and D. Perrotti, The biology of CML blast crisis, Blood, vol.103, pp.4010-4022, 2004.

C. H. Jamieson, Granulocyte-macrophage progenitors as candidate leukemic stem cells in blastcrisis CML, N. Engl. J. Med, vol.351, pp.657-667, 2004.

M. Baccarani, European LeukemiaNet recommendations for the management of chronic myeloid leukemia, Blood, vol.122, p.872, 2013.

J. E. Sokal, Prognostic discrimination in 'good-risk' chronic granulocytic leukemia, Blood, vol.63, pp.789-799, 1984.

A. Pallera, NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1, J Natl Compr Canc Netw, vol.14, pp.1505-1512, 2016.

J. Hasford, Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score, Blood, vol.118, pp.686-692, 2011.

M. Pfirrmann, Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia, Leukemia, vol.30, pp.48-56, 2016.

D. Rea, First-line imatinib mesylate in patients with newly diagnosed accelerated phase-chronic myeloid leukemia, Leukemia, vol.26, pp.2254-2259, 2012.

A. Fabarius, Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: longterm observation of 1151 patients from the randomized CML Study IV, Blood, vol.118, pp.6760-6768, 2011.

S. Luatti, Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis, Blood, vol.120, pp.761-767, 2012.

, Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists' Collaborative Group, J. Natl. Cancer Inst, vol.89, pp.1616-1620, 1997.

F. Guilhot, Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group, N. Engl. J. Med, vol.337, pp.223-229, 1997.

M. Talpaz, J. Mercer, and R. Hehlmann, The interferon-alpha revival in CML, Ann. Hematol, vol.94, issue.2, pp.195-207, 2015.

R. T. Silver, An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the, Blood, vol.94, pp.1517-1536, 1999.

J. Pavlu, R. M. Szydlo, J. M. Goldman, and J. F. Apperley, Three decades of transplantation for chronic myeloid leukemia: what have we learned?, Blood, vol.117, pp.755-763, 2011.

J. M. Goldman, Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase, J. Clin. Oncol, vol.28, pp.1888-1895, 2010.

K. Claiborn and . Brian, Druker and Charles Sawyers receive the 2011 ASCI/Stanley J. Korsmeyer Award, J Clin Invest, vol.121, pp.1227-1228, 2011.

H. Kantarjian and J. E. Cortes, Complete cytogenetic response, not deep molecular response, is associated with survival in chronic myeloid leukemia, J. Clin. Oncol, vol.32, p.3077, 2014.

A. Hochhaus, Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia, New England Journal of Medicine, vol.376, pp.917-927, 2017.

K. Sasaki, Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosinekinase inhibitor era: analysis of patient data from six prospective clinical trials, Lancet Haematol, vol.2, pp.186-193, 2015.

C. Gambacorti-passerini, Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib, J. Natl. Cancer Inst, vol.103, pp.553-561, 2011.

E. Jabbour and H. Kantarjian, Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring, American Journal of Hematology, vol.93, pp.442-459, 2018.

M. Deininger, International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib, Blood, vol.114, pp.1126-1126, 2009.

S. G. O'brien, Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia, N. Engl. J. Med, vol.348, pp.994-1004, 2003.

H. Kantarjian, Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia, N. Engl. J. Med, vol.362, pp.2260-2270, 2010.

J. E. Cortes, Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial, Journal of Clinical Oncology, vol.34, p.2333, 2016.

G. Saglio, Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia, N. Engl. J. Med, vol.362, pp.2251-2259, 2010.

J. E. Cortes, Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial, J Clin Oncol, vol.36, pp.231-237, 2018.

A. Hochhaus, Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy, Blood, vol.109, pp.2303-2309, 2007.

N. P. Shah, Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia, JCO, vol.26, pp.3204-3212, 2008.

N. P. Shah, Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034, Am. J. Hematol, vol.91, pp.869-874, 2016.

H. M. Kantarjian, Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results, Blood, vol.117, pp.1141-1145, 2011.

J. E. Cortes, Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosomepositive chronic myeloid leukemia patients with resistance or intolerance to imatinib, Blood, vol.118, pp.4567-4576, 2011.

J. E. Cortes, Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial, Journal of Clinical Oncology, vol.30, p.3486, 2012.

J. E. Cortes, A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias, N. Engl. J. Med, vol.369, pp.1783-1796, 2013.

F. Mahon and G. Etienne, Deep Molecular Response in Chronic Myeloid Leukemia: The New Goal of Therapy?, Clin Cancer Res, vol.20, pp.310-322, 2014.

D. Rea, Management of adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukemia, Ann. Hematol, vol.94, issue.2, pp.149-158, 2015.

D. Montani, Pulmonary Arterial Hypertension in Patients Treated by DasatinibClinical Perspective, Circulation, vol.125, pp.2128-2137, 2012.

A. Quintás-cardama, Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure, J. Clin. Oncol, vol.25, pp.3908-3914, 2007.

J. P. Radich, A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia, Blood, vol.120, pp.3898-3905, 2012.

F. J. Giles, Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis, Leukemia, vol.27, pp.1310-1315, 2013.

L. Noens, Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study, Blood, vol.113, pp.5401-5411, 2009.

D. Marin, Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib, J. Clin. Oncol, vol.28, pp.2381-2388, 2010.

A. R. Ibrahim, Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy, Blood, vol.117, pp.3733-3736, 2011.

F. Efficace, Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study, Br. J. Cancer, vol.107, pp.904-909, 2012.

F. Mahon, Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial, Lancet Oncol, vol.11, pp.1029-1035, 2010.

G. Etienne, Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia, J. Clin. Oncol, vol.35, pp.298-305, 2017.

P. Rousselot, Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease, J. Clin. Oncol, vol.32, pp.424-430, 2014.

D. M. Ross, Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study, Blood, vol.122, pp.515-522, 2013.

A. Hochhaus, Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study, Leukemia, vol.31, pp.1525-1531, 2017.

D. M. Ross, Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study, J. Cancer Res. Clin. Oncol, vol.144, pp.945-954, 2018.

D. Rea, Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study, Blood, vol.129, pp.846-854, 2017.
URL : https://hal.archives-ouvertes.fr/hal-02050833

S. Saussele, Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial, Lancet Oncol, issue.18, p.30192, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01859932

A. Hochhaus, Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann. Oncol, vol.28, pp.41-51, 2017.

D. Rea, Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group, Cancer, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01860448

M. Copland, Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction, Blood, vol.107, pp.4532-4539, 2006.

A. Hamilton, Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival, Blood, vol.119, pp.1501-1510, 2012.

J. Chomel, Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease, Blood, vol.118, pp.3657-3660, 2011.

T. L. Holyoake and D. Vetrie, The chronic myeloid leukemia stem cell: stemming the tide of persistence, Blood, vol.129, pp.1595-1606, 2017.

E. Cayssials and F. Guilhot, Chronic Myeloid Leukemia: Immunobiology and Novel Immunotherapeutic Approaches, BioDrugs, vol.31, pp.143-149, 2017.

N. P. Shah, Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis, Cancer Cell, vol.14, pp.485-493, 2008.

L. J. Lombardo, Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays, J. Med. Chem, vol.47, pp.6658-6661, 2004.

T. O'hare, In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants, Cancer Res, vol.65, pp.4500-4505, 2005.

J. S. Tokarski, The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants, Cancer Res, vol.66, pp.5790-5797, 2006.

Y. Ishida, Pharmacokinetics and pharmacodynamics of dasatinib in the chronic phase of newly diagnosed chronic myeloid leukemia, Eur J Clin Pharmacol, vol.72, pp.185-193, 2016.

A. Hochhaus, Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib, Leukemia, vol.22, pp.1200-1206, 2008.

J. F. Apperley, Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial, JCO, vol.27, pp.3472-3479, 2009.

J. Cortes, Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis, Blood, vol.109, pp.3207-3213, 2007.

E. Jabbour, Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION), Blood, vol.123, pp.494-500, 2014.

H. Kantarjian, Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial, Blood, vol.109, pp.5143-5150, 2007.

N. P. Shah, Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib, Haematologica, vol.95, pp.232-240, 2010.

P. Rousselot, Dasatinib daily dose optimization based on residual drug levels resulted in reduced risk of pleural effusions and high molecular response rates: final results of the randomized Optim dasatinib trial, FERRATA STORTI FOUNDATION VIA GIUSEPPE BELLI 4, 27100, vol.99, pp.237-238, 2014.

P. L. Rosée, Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib, Ann Hematol, vol.92, pp.1345-1350, 2013.

F. P. Santos, Clinical Impact of Dose Reductions and Interruptions of Second-Generation Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukaemia, Br J Haematol, vol.150, pp.303-312, 2010.

M. Imamura, Efficacy of intermittently administered dasatinib with a reduced dose in an elderly patient with chronic myeloid leukemia, Geriatrics & gerontology international, vol.16, pp.768-770, 2016.

T. Hughes, Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results, Blood, vol.108, pp.28-37, 2006.

, Common Terminology Criteria for Adverse Events (CTCAE) | Common Terminology Criteria for Adverse Events (CTCAE) | Protocol Development | CTEP, p.28, 2018.

N. K. Aaronson, The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology, J. Natl. Cancer Inst, vol.85, pp.365-376, 1993.

P. Fayers, European Organisation for Research and Treatment of Cancer, EORTC QLQ-C30 Scoring Manual, 2001.

D. F. Cella, The Functional Assessment of Cancer Therapy scale: development and validation of the general measure, J. Clin. Oncol, vol.11, pp.570-579, 1993.

K. Webster, D. Cella, and K. Yost, The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation, Health Qual Life Outcomes, vol.1, p.79, 2003.

F. L. Loth, Cancer patients' understanding of longitudinal EORTC QLQ-C30 scores presented as bar charts, Patient Education and Counseling, vol.99, pp.2012-2017, 2016.

M. Talpaz, G. Saglio, E. Atallah, and P. Rousselot, Dasatinib dose management for the treatment of chronic myeloid leukemia

R. E. Clark, De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial, Lancet Haematol, vol.4, pp.310-316, 2017.

M. G. Inc, . Results, . The, . Study, . De-escalation et al., , p.23, 2018.

T. P. Hughes and D. M. Ross, Moving treatment-free remission into mainstream clinical practice in CML, Blood, vol.128, pp.17-23, 2016.

J. Richter, Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome?, J. Clin. Oncol, vol.32, pp.2821-2823, 2014.

P. Rousselot, Attempt to early discontinue dasatinib first line in chronic phase CML patients in early molecular response and included in the prospective OPTIM-dasatinib trial, FERRATA STORTI FOUNDATION VIA GIUSEPPE BELLI 4, 27100, vol.100, pp.230-230, 2015.

S. Aksu, The Clinical Impact of Low Doses of Dasatinib in Patients with Chronic Myeloid Leukemia, International Journal of Hematology & Oncology/UHOD: Uluslararasi Hematoloji Onkoloji Dergisi, vol.22, 2012.

M. Lauseker, R. Gerlach, M. Tauscher, and J. Hasford, Improved survival boosts the prevalence of chronic myeloid leukemia: predictions from a population-based study, J Cancer Res Clin Oncol, vol.142, pp.1441-1447, 2016.

T. Sacha, A multicenter prospective study on efficacy and safety of imatinib generics: A report from Polish Adult Leukemia Group imatinib generics registry, Am. J. Hematol, vol.92, pp.125-128, 2017.

M. Danthala, Generic Imatinib in Chronic Myeloid Leukemia: Survival of the Cheapest, Clin Lymphoma Myeloma Leuk, vol.17, pp.457-462, 2017.

, Traitement de maintenance par des doses alternées de dasatinib dans la leucémie myéloïde chronique Résumé : Les inhibiteurs de tyrosine kinase (ITKs) induisent des réponses durables chez les patients atteints de leucémie myéloïde chronique (LMC)

, L'objectif principal de notre étude était de déterminer la survie sans perte de la RMM (BCR-ABL1 IS >0.1%) en maintenance dans une cohorte rétrospective R puis par un essai prospectif P

, La durée médiane d'administration du dasatinib était de 44.8 (5.6 -116) et 47.8 (32.7 -88.4) mois et la dose médiane quotidienne de 50 et 100 mg dans les cohortes R et P respectivement. Avec un suivi médian de 24 et 30.7 mois dans les cohortes R et P, la survie sans perte de la RMM à 2 ans était de 80, Une cohorte de 100 patients a été étudiée dont 64 dans la cohorte R et 36 dans la cohorte P (critères d'inclusion identiques à ceux de l'étude d'arrêt EUROSKI soit au moins 3 ans de traitement et 1 an de RM 4 )

, La maintenance apparait comme une alternative à l'arrêt du dasatinib chez les patients en 1 ère ou seconde ligne

, Mots clés : leucémie myéloïde chronique, inhibiteurs de tyrosine kinase, réponse moléculaire, maintenance. Maintenance therapy with dasatinib administrated every other day in chronic myeloid leukemia Abstract: Tyrosine kinase inhibitors (TKIs) induce deep lasting molecular responses in patients with chronic myeloid leukemia (CML). However, 60% of patients eligible to TKIs discontinuation will experience loss of major molecular response (MMR). We evaluated maintenance therapy with dasatinib administrated every other day as an alternative to discontinuation